Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Clinical Trials: Retatrutide Results So Far The most compelling evidence for Retatrutides potential comes from a 2023 Phase 2 trial published in the New England Journal of Medicine
The trial enrolled over 1,900 participants and remains one of the most cited studies in obesity pharmacotherapy
Results Dual function of GLP-1 receptor agonist peptide and anti-PCSK9 antibody fusions Based on the critical requirement for a free N-terminus on the GLP-1 peptide for receptor activation 11 , we genetically fused a DPP-4-resistant GLP-1R agonist peptide, similar to the one used in the Fc fusion molecule LY2189265 12 , to either the heavy or light chain variable domain of neutralising anti-PCSK9 antibodies (Fig
What happens during IV therapy
The mechanical stress denatures the peptide
US$ 27.92
US$ 28.51
US$ 24.87
US$ 28.33
.jpg)
US$ 23.66
US$ 28.78
US$ 28.53
US$ 28.53
